Ocrelizumab-related organizing pneumonia in multiple sclerosis: insights from a case series and literature review.
Enrico Petza, Simone Guerrieri, Veronica Marino et al.
✦ AI-curated · Sources linked
Case in brief
A case series of five multiple sclerosis patients treated with ocrelizumab developed organizing pneumonia (OP) after a mean treatment duration of 5.1 years. Clinical symptoms included persistent fever and nonproductive cough, with chest CT revealing patchy ground-glass opacities. All patients were treated with prednisone, leading to initial improvement, but four experienced respiratory relapses and residual lung abnormalities during follow-up. Ocrelizumab was discontinued in all cases.
Diagnostic / clinical pearl
Clinicians should be aware of the potential for organizing pneumonia in patients receiving ocrelizumab, particularly when presenting with persistent fever and respiratory symptoms.
Why it matters
This case series highlights the need for vigilance regarding pulmonary complications in patients treated with ocrelizumab, as early recognition and management may impact patient outcomes.